Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2019

Stockholders' Equity Note [Abstract]

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follows:

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019		2018
Included in cost of revenue	$	—	$	(9,143	)	$	—	$	30,488
Included in research and development expense	$	86,058	$	111,812		$	196,139	$	507,521
Included in selling, general and administrative expense	62,776		118,631			152,763		1,089,422
Total stock-based compensation expense	$	148,834	$	221,300		$	348,902	$	1,627,431

Schedule of Assumptions to Estimate Fair Value of Stock Option Awards

The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:

	Six Months Ended June 30,
	2019		2018
Risk-free interest rate	1.8	%	2.43	%
Dividend yield	0	%	0	%
Expected volatility	95	%	90	%
Expected term	5.9 years		5.2 years

Summary of Stock Option Activity and of Changes in Stock Options Outstanding

A summary of stock option activity and changes in stock options outstanding is presented below:

	Total Options		Weighted-Average Exercise Price Per Share		Intrinsic Value
Balance outstanding, December 31, 2018	83,345		$	146.09	$	—
Granted	961,313		$	2.50
Canceled / Forfeited	(11,384	)	$	70.82
Balance outstanding, June 30, 2019	1,033,274		$	13.34	$	19,059
Exercisable at June 30, 2019	74,486		$	149.43	$	—

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of the RSU activity is presented below:

	Number of Shares		Weighted-Average Grant Date Fair Value Per Share		Intrinsic Value
Non-vested RSUs outstanding, December 31, 2018	30,132		$	14.36	$	95,005
Granted	167		$	4.04
Vested	(10,795	)	$	13.67	$	41,233
Forfeited	(5,317	)	$	13.04
Non-vested RSUs outstanding, June 30, 2019	14,187		$	15.25	$	35,468

Summary of Warrant Activity and Changes in Warrants Outstanding

A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:

	Total Warrants		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term
Balance outstanding, December 31, 2018	3,649,341		$	8.91	4.4
Granted	1,408,510		$	3.50
Exercised	(653,666	)	$	5.96
Balance outstanding, June 30, 2019	4,404,185		$	7.62	4.3